| Literature DB >> 24644438 |
Mitra Jelvehgari1, Leila Barghi2, Farhad Barghi3.
Abstract
BACKGROUND: Chlorpheniramine maleate (CM) is widely used as an antihistaminic drug but it is very bitter and as yet no mouth dissolving/disintegrating taste-masked preparation that might be useful for pediatric and geriatric patients is available in the market.Entities:
Keywords: Aluminium; Calcium; Chlorpheniramine; Taste
Year: 2014 PMID: 24644438 PMCID: PMC3957142 DOI: 10.17795/jjnpp-12530
Source DB: PubMed Journal: Jundishapur J Nat Pharm Prod ISSN: 1735-7780
Chlorpheniramine Maleate Microparticle Formulations Prepared by the Ionotropic Gelation Method With Different Sodium Alginate:Chitosan Ratios, Without Chitosan and Ion (Ca2+) [a]
| Formulations | Na-Alg:CS Ratio | Cross-linked Insoluble Complexes | |||||
|---|---|---|---|---|---|---|---|
| Aqueous Phase | Ionotropic Gelation Agents | ||||||
| CM, g | Water, mL | Na-Alg, g | Chitosan, g | Acetic Solution (%0.5 v/v), mL | Calcium Chloride, g | ||
|
| 1:0.27 | 0.25 | 100 | 1.2 | 0.325 | 100 | 1.3 |
|
| 1:0.54 | 0.25 | 100 | 1.2 | 0.650 | 100 | 1.3 |
|
| 1:1.1 | 0.25 | 100 | 1.2 | 1.3 | 100 | 1.3 |
|
| 0.25 | 100 | 1.2 | 100 | 0.65 | ||
|
| 0.25 | 100 | 1.2 | 100 | 1.3 | ||
|
| 0.25 | 100 | 1.2 | 100 | 2.6 | ||
a Abbreviations: Na-Alg, sodium alginate; CS: chitosan; CM, chlorpheniramine.
Chlorpheniramine Maleate Microparticle Formulations Prepared by the Ionotropic Gelation Method With Different Sodium Alginate:Chitosan Ratios, Without Chitosan and Ions (Al3+) [a]
| Formulations | Na-Alg:CS Ratio | Cross-linked Insoluble Complexes | |||||
|---|---|---|---|---|---|---|---|
| Aqueous Phase | Aqueous Phase | ||||||
| Chlorpheniramine, g | Water, mL | Na-Alg, g | Chitosan, g | Acetic Solution (%0.5 v/v), mL | Aluminum Chloride, g | ||
|
| 1 :0.27 | 0.25 | 100 | 1.2 | 0.325 | 100 | 1.3 |
|
| 1:0.54 | 0.25 | 100 | 1.2 | 0.650 | 100 | 1.3 |
|
| 1:1.1 | 0.25 | 100 | 1.2 | 1.3 | 100 | 1.3 |
|
| 0.25 | 100 | 1.2 | 100 | 1.3 | ||
a Abbreviations: Na-Alg, sodium alginate; CS, chitosan.
Effect of Sodium Alginate:Chitosan Ratio and Ions (Ca2+, Al3+) on the Content, Production Yield and Particle Size of Chlorpheniramine Microparticles
| Form-ulations | Chitosan, g | Na-Alg:Cs Ratio | Production Yield, % (SD) | Theoretical Drug Content, % | Mean Amount of Drug Entrapped, % (SD) | Loading Efficiency , % (SD) | Mean Particlesize, µm (SD) |
|---|---|---|---|---|---|---|---|
|
| 0.325 | 1 :0.27 | 40 (3.65) | 8.13 | 1.7 (0.27) | 20.91 (3.78) | 644.54 (59.15) |
|
| 0.65 | 1:0.54 | 49.41 (5.69) | 7.35 | 2.32 (0.34) | 31.56 (2.89) | 728.29 (48.27) |
|
| 1.3 | 1:1.1 | 51.6 (6.31) | 6.17 | 3.84 (0.65) | 62.24 (3.62 | 769.09 (41.37 |
|
| 55.45 (5.63) | 11.90 | 11.21 (3.85) | 94.20 (7.48 | 731.62 (39.96) | ||
|
| 58.18 (6.39) | 9.09 | 6.17 (1.12) | 67.88 (4.69) | 1052.44 (57.73) | ||
|
| 53.09 (4.32) | 6.17 | 5.09 (1.47) | 82.5 (7.25) | 1061 (45.27) | ||
|
| 0.325 | 1 :0.27 | 46.83 (4.12 | 8.13 | 6.19 (0.65) | 76.14 (6.25) | 2251.85 (11.96) |
|
| 0.65 | 1:0.54 | 49.41 (4.89) | 7.35 | 5.92 (0.47) | 80.54 (6.89) | 1288.25 (11.79) |
|
| 1.3 | 1:1.1 | 45.43 (4.28) | 6.17 | 2.95 (0.26) | 47.81 (5.45) | 1513.56 (10.22) |
|
| 44 (5.91) | 9.09 | 9.77 (2.11) | 107.48 (8.19) | 912.01 (11.79) |
Equation 2
Figure 1.Optical Microscopic Photograph of Spherical Microspheres
A. F3 (1.3 g chitosan and 1.3 g calcium chloride) and B. F5 (0.325 g chitosan and 1.3 g aluminum chloride) formulations at 10x.
Figure 2.a. DSC Thermogram of Chlorpheniramine; b. Na alginate; c. Calcium chloride; d. Chitosan; e. F3; f. Physical Mixture F3; g. Aluminum chloride; h. Physical Mixture F’1; i. F’1
Figure 3.a. X-ray Diffraction of Chlorpheniramine; b. Na alginate; c. Chitosan; d. Calcium chloride; e. Physical Mixture F3, f. F3; aʹ. Aluminum chloride; bʹ. Physical Mixture F’1; cʹ. F’1.
Figure 4.a. FTIR Spectrum of Chlorpheniramin; b. Na Alginat; c. Chitosan; d. Calcium Chloride; e. Physical Mixture F3, f. F3 (f); aʹ. Aluminum Chloride; bʹ. Physical Mixture F’1; cʹ. F’1
Taste Recognition Threshold Determination [a ]
| Number of Volunteers | Concentration, µg/mL | |||||
|---|---|---|---|---|---|---|
| 50 | 100 | 150 | 250 | 350 | 450 | |
|
| - | - | + | ++ | +++ | +++++ |
|
| - | + | ++ | +++ | ++++ | +++++ |
|
| - | + | ++ | ++++ | +++++ | +++++ |
|
| - | + | ++ | +++ | +++ | +++++ |
|
| - | ± | ++ | +++ | ++++ | +++++ |
|
| - | + | ++ | ++++ | ++++ | +++++ |
|
| - | ± | + | ++ | ++++ | +++++ |
|
| - | + | ++ | ++ | ++++ | +++++ |
a - = good, ± = tasteless, + = slightly bitter, ++ = moderate bitter, +++ = bitter, ++++ = very bitter, +++++ = awful.
Taste Masking Ability of Various Formulations
| Formulations | Chitosan, g | CaCl2/Alcl3, g | Taste | Concentration, µg/mL |
|---|---|---|---|---|
|
| 0.325 | 1.3 CaCl2 | Good | 27.71 |
|
| 0.65 | 1.3 CaCl2 | Good | 10.70 |
|
| 1.3 | 1.3 CaCl2 | Good | 10.44 |
|
| 0.65 CaCl2 | Good | 45.44 | |
|
| 1.3 CaCl2 | Good | 49.43 | |
|
| 2.6 CaCl2 | Good | 30.91 | |
|
| 0.325 | 1.3 AlCl3 | Good | 9.65 |
|
| 0.65 | 1.3 AlCl3 | Good | 10.98 |
|
| 1.3 | 1.3 AlCl3 | Good | 13.98 |
|
| 1.3 AlCl3 | Good | 17.71 |
Figure 5.A. Cumulative Percent Release of Chlorpheniramine From Microspheres Prepared With Different Sodium Alginate:chitosan Ratios and Ion Ca2+/Al3+; B. Without Chitosan and Ion Ca2+; C. Untreated Chlorpheniramine and Commercial® Tablet
Comparison of Various Release Characteristics of Chlorpheniramine From Different Microsphere Formulations, Untreated Chlorpheniramine Powder and Commercial® Tablet a
| Formulations | Chitosan, g | Cacl2/Alcl3, g | Rel5, % | Rel8, % | DE | t50%, min |
|
|---|---|---|---|---|---|---|---|
|
| 0.325 | 1.3 CaCl2 | 1.99 | 71.81 | 47.30 | 163.82 | 63.64 |
|
| 0.65 | 1.3 CaCl2 | 10.61 | 71.34 | 40.32 | 196.79 | 66.96 |
|
| 1.3 | 1.3 CaCl2 | 3.08 | 59.29 | 36.53 | 184.28 | 70.18 |
|
| 0.65 CaCl2 | 37.93 | 43.62 | 41.20 | 26.61 | 59.64 | |
|
| 1.3 CaCl2 | 44.97 | 77.08 | 64.19 | 80.28 | 40.98 | |
|
| 2.6 CaCl2 | 58.29 | 91.18 | 76.74 | 76 | 32.24 | |
|
| 0.325 | 1.3 AlCl3 | 1.05 | 59.37 | 27.94 | 254.09 | 78.80 |
|
| 0.65 | 1.3 AlCl3 | 1.74 | 48.71 | 30.75 | 176.94 | 76.05 |
|
| 1.3 | 1.3 AlCl3 | 4.25 | 41.89 | 32.64 | 105.92 | 72.5 |
|
| 1.3 AlCl3 | 3.60 | 62.24 | 42.02 | 155.91 | 66.06 | |
|
| 110.99 | 114.06 | 112.38 | 7.08 | 13.39 | ||
|
| 35.76 | 111.35 | 106.12 | 22.54 | 0 |
aAbbreviations: Rel, release characteristics.
Fitting Parameters of the In vitro Release Data to Various Release Kinetics Models [a ]
| Formulation | ORDER | MPE, % | RSQ | Slope | Intercept | K |
|---|---|---|---|---|---|---|
|
| Peppas | 14.44 | 0.876 | 0.483 | -3.934 | 0.0196 |
|
| Square root of mass | 7.44 | 0.97 | 0.001 | 0.044 | |
|
| Peppas | 5.28 | 0.984 | 0.450 | -3.410 | 0.0330 |
|
| Non-Conventional | 1.41 | 0.89 | 0 | 0.071 | 0.0000 |
|
| Peppas | 4.03 | 0.931 | 0.532 | -3.854 | 0.0212 |
|
| Peppas | 0.21 | 0.573 | 0.003 | -3.410 | -0.5430 |
|
| Non-Conventional | 20.37 | 0.954 | 0.001 | 0.003 | 0.0010 |
|
| Weibull | 15.40 | 0.961 | 0.757 | -5.081 | 0.0012 |
|
| Log-probability | 11.93 | 0.950 | 0.309 | -2.062 | |
|
| Log-probability | 9.12 | 0.976 | 0.441 | -2.508 |
a Abbreviations: MPE, mean percent error; RSQ, readability strength quality.